3-MMC: Difference between revisions

Line 3:

'''3-Methylmethcathinone''' (also known as '''3-MMC''' or '''metaphedrone'''<ref>{{cite journal | vauthors=((Adamowicz, P.)), ((Gieroń, J.)), ((Gil, D.)), ((Lechowicz, W.)), ((Skulska, A.)), ((Tokarczyk, B.)) | journal=Journal of Analytical Toxicology | title=3-Methylmethcathinone—Interpretation of Blood Concentrations Based on Analysis of 95 Cases | volume=40 | issue=4 | pages=272–276 | date= May 2016 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkw018 | issn=0146-4760 | doi=10.1093/jat/bkw018}}</ref>) is a novel [[psychoactive class::stimulant]]-[[psychoactive class::entactogen]] substance of the [[chemical class::cathinone]] class. It is a structural analog of [[mephedrone]] (4-MMC). The mechanism of action is not fully studied, but [[dopamine]] and [[serotonin]] and norepinephrine releasing activity is known to be involved.

3-MMC first appeared on the online [[research chemical]] market shortly after the banning of the massively popular mephedrone. ~~It is one of many cathinone analogs that were released~~ in ~~the 2010s.~~{{citation ~~needed~~}} It is a prominent example of a contemporary [[designer drug]] specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors.

3-MMC first appeared on the online [[research chemical]] market shortly after the banning of the massively popular mephedrone. Its first emergence was recorded in Europe in 2012<ref>{{citation | vauthors=((World Health Organisation)), ((Expert Committee on Drug Dependence)) | title=Critical review report: 3-Methylmethcathinone (3-MMC) | date= October 2022 | url=https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/3-mmc_draft.pdf}}</ref>. It is a prominent example of a contemporary [[designer drug]] specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors.

[[Subjective effects]] include [[stimulation]], [[anxiety suppression]], [[disinhibition]], [[empathy, affection, and sociability enhancement|enhanced empathy and sociability]], [[muscle relaxation|relaxation]], [[increased libido]], and [[euphoria]]. The effects are reported to be similar to those of mephedrone, which is sometimes described as a hybrid of [[MDMA]] and [[cocaine]].

@@ Line 3: / Line 3: @@
 '''3-Methylmethcathinone''' (also known as '''3-MMC''' or '''metaphedrone'''<ref>{{cite journal | vauthors=((Adamowicz, P.)), ((Gieroń, J.)), ((Gil, D.)), ((Lechowicz, W.)), ((Skulska, A.)), ((Tokarczyk, B.)) | journal=Journal of Analytical Toxicology | title=3-Methylmethcathinone—Interpretation of Blood Concentrations Based on Analysis of 95 Cases | volume=40 | issue=4 | pages=272–276 | date= May 2016 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkw018 | issn=0146-4760 | doi=10.1093/jat/bkw018}}</ref>) is a novel [[psychoactive class::stimulant]]-[[psychoactive class::entactogen]] substance of the [[chemical class::cathinone]] class. It is a structural analog of [[mephedrone]] (4-MMC). The mechanism of action is not fully studied, but [[dopamine]] and [[serotonin]] and norepinephrine releasing activity is known to be involved.
--MMC first appeared on the online [[research chemical]] market shortly after the banning of the massively popular mephedrone. It is one of many cathinone analogs that were released in the 2010s.{{citation needed}} It is a prominent example of a contemporary [[designer drug]] specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors.
+-MMC first appeared on the online [[research chemical]] market shortly after the banning of the massively popular mephedrone. Its first emergence was recorded in Europe in 2012<ref>{{citation | vauthors=((World Health Organisation)), ((Expert Committee on Drug Dependence)) | title=Critical review report: 3-Methylmethcathinone (3-MMC) | date= October 2022 | url=https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/3-mmc_draft.pdf}}</ref>. It is a prominent example of a contemporary [[designer drug]] specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors.
 [[Subjective effects]] include [[stimulation]], [[anxiety suppression]], [[disinhibition]], [[empathy, affection, and sociability enhancement|enhanced empathy and sociability]], [[muscle relaxation|relaxation]], [[increased libido]], and [[euphoria]]. The effects are reported to be similar to those of mephedrone, which is sometimes described as a hybrid of [[MDMA]] and [[cocaine]].